
Global Microbiome Diagnostics Market Size, Share & Trends Analysis Report By Application, By Product (Reagents & Kits and Instruments), By Sample (Fecal, Saliva, Skin, and Others), By Technology, By End User, By Regional Outlook and Forecast, 2023 - 2030
Description
Global Microbiome Diagnostics Market Size, Share & Trends Analysis Report By Application, By Product (Reagents & Kits and Instruments), By Sample (Fecal, Saliva, Skin, and Others), By Technology, By End User, By Regional Outlook and Forecast, 2023 - 2030
The Global Microbiome Diagnostics Market size is expected to reach $416.1 million by 2030, rising at a market growth of 17.5% CAGR during the forecast period.
Microbiome diagnostics offer a complementary approach to traditional diagnostic modalities by providing insights into the gut microbiome’s role in metabolic health, facilitating early detection of metabolic disturbances, and stratifying individuals based on their metabolic risk profiles. Thus, the metabolic diseases segment acquired $16,399.8 thousand revenue in 2022. Metabolic diseases pose diagnostic challenges due to their multifactorial nature, heterogeneous presentation, and overlapping symptoms.
Microbiome diagnostics have applications across many healthcare areas beyond traditional fields like gastroenterology. As research progresses, the microbiome’s influence on various aspects of human health becomes increasingly apparent. It enables clinicians to develop personalized interventions, such as targeted probiotics, prebiotics, or dietary modifications, to optimize patient health outcomes.
Additionally, Technological advancements, particularly in next-generation sequencing (NGS) technologies, enable higher precision and resolution in microbiome analysis. Improved sequencing platforms and algorithms allow for detecting rare microbial taxa and subtle changes in microbial community composition, enhancing the diagnostic accuracy of microbiome tests. Hence, ongoing technological advancements in microbiome diagnostics drive the market’s growth.
Further, the COVID-19 pandemic disrupted research activities and clinical trials across various fields, including microbiome diagnostics. Many research projects and clinical studies were delayed, suspended, or canceled due to restrictions on laboratory access, reduced funding, and prioritization of COVID-19 research efforts. Some companies expanded into microbiome diagnostics to capitalize on the growing interest in this field and to meet the demand for novel diagnostic solutions. Thus, the COVID-19 pandemic moderately impacted the market.
However, the interactions between the human host and the microbiome are highly complex and dynamic, influenced by numerous factors such as genetics, diet, lifestyle, environment, and immune function. Understanding the intricate relationships between microbial communities and host physiology, metabolism, and immune responses is challenging. Thus, a limited understanding of microbiome-host interactions hampers the market’s growth.
By Application Analysis
By application, the market is divided into disease diagnostics and research application. In 2022, the disease diagnostics segment registered the largest 52.2% share in the market. It enables a precision medicine approach to disease diagnosis by assessing individual microbial profiles and their associations with specific health conditions.
By Disease Diagnostics Analysis
The disease diagnostics segment is subdivided into gastrointestinal disorders, metabolic diseases, and others. In 2022, the gastrointestinal disorders segment attained a 49% share in the microbiome diagnostics market. Gastrointestinal disorders, including inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux disease (GERD), and colorectal cancer, affect millions of people worldwide.
By Product Analysis
Based on product, the market is bifurcated into reagents & kits and instruments. The instruments segment attained a substantial 37.2% revenue share in the market in 2022. Technological advancements have led to the development of sophisticated instruments tailored for microbiome analysis.
By Sample Analysis
Based on sample, the market is categorized into fecal, saliva, skin, and others. In 2022, the fecal segment registered the highest 51.4% revenue share in the market. Fecal samples are a rich source of microbial diversity, containing diverse bacteria, fungi, viruses, and other microorganisms inhabiting the gastrointestinal tract.
By Technology Analysis
On the basis of technology, the market is segmented into 16S rRNA sequencing, shot gun metagenomics, metatranscriptomics, and others. In 2022, the shot gun metagenomics segment attained a 21.4% revenue share in the market.
By End User Analysis
Based on end user, the market is divided into hospitals, academic & research institutes, and biotechnology & pharmaceutical companies. The hospitals segment attained a 49% revenue share in the market in 2022. Hospitals are primary centers for diagnosing and treating various medical conditions, including infectious diseases, chronic illnesses, and complex disorders.
By Regional Analysis
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed a 51% revenue share in the market in 2022. There has been increasing recognition of the microbiome’s role in human health and disease among healthcare professionals, researchers, and the general population in North America.
Recent Strategies Deployed in the Market
- Dec-2023: Genetic Analysis AS collaborated with Comono AS, an IT service and IT consulting firm. Under this collaboration, Genetic Analysis AS would evolve a digital line of work platform for the consumer market for testing of microbiome. Moreover, Genetic Analysis AS would enter into the microbiome consumer testing market to offer distinctive and accessible testing services.
- Nov-2023: Viome Life Sciences acquired Naring Health, a high-tech health and wellness firm. Through this acquisition, Viome Life Sciences would enable its user’s accurate insight into their biochemical identity.
- May-2023: Microba Life Sciences collaborated with Mainz Biomed N.V., a Germany-based molecular diagnostic company. Under this collaboration, both companies would accelerate the development of the PancAlert project by using bioinformatic tools and a metagenomic sequencing mechanism to locate microbiome biomarkers for the detection of pancreatic cancer.
- Mar-2023: Becton, Dickinson, and Company received FDA approval for a Vaginal Panel, an extensive diagnostic test that identifies causes of vaginitis. The BD COR system allows STI testing and critical health of women by strengthening patient management and laboratory operations with the latest molecular diagnostic features.
- Mar-2023: Microba Life Sciences unveiled MetaXplore, a series of testing products such as MetaXplore GI and MetaXplore GI Plus. With the launch of MetaXplore, Microba would be able to provide healthcare professionals with new technology products for diagnosing gastrointestinal health and analysis of metagenomic-operated gut microbiota.
- Jul-2022: Viome Life Sciences launched the Full Body Intelligence Test, an advanced comprehensive health and microbiome-based test. With the launch of this product oral and gut microbiome tests would be done at homes. Additionally, the product would also identify the root causes of cancer, aging, and chronic diseases.
- Illumina, Inc.
- Becton, Dickinson and Company
- Genetic Analysis AS
- Microba Life Sciences Limited
- BioMe Oxford Ltd
- Viome Life Sciences, Inc.
- GoodGut S.L.U. (HIPRA, S.A.)
- Sun Genomics
- Origin Sciences Limited
- Decode Age
By Application
- Disease Diagnostics
- Gastrointestinal Disorders
- Metabolic Diseases
- Others
- Research Application
- Reagents & Kits
- Instruments
- Fecal
- Saliva
- Skin
- Others
- 16S rRNA Sequencing
- Shot Gun Metagenomics
- Metatranscriptomics
- Others
- Hospitals
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
358 Pages
- Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 Global Microbiome Diagnostics Market, by Application
- 1.4.2 Global Microbiome Diagnostics Market, by Product
- 1.4.3 Global Microbiome Diagnostics Market, by Sample
- 1.4.4 Global Microbiome Diagnostics Market, by Technology
- 1.4.5 Global Microbiome Diagnostics Market, by End User
- 1.4.6 Global Microbiome Diagnostics Market, by Geography
- 1.5 Methodology for the research
- Chapter 2. Market at a Glance
- 2.1 Key Highlights
- Chapter 3. Market Overview
- 3.1 Introduction
- 3.1.1 Overview
- 3.1.1.1 Market Composition and Scenario
- 3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Opportunities
- 3.2.3 Market Restraints
- 3.2.4 Market Challenges
- 3.3 Porter Five Forces Analysis
- Chapter 4. Strategies Deployed in Microbiome Diagnostics Market
- Chapter 5. Global Microbiome Diagnostics Market by Application
- 5.1 Global Disease Diagnostics Market by Region
- 5.2 Global Microbiome Diagnostics Market by Disease Diagnostics Type
- 5.2.1 Global Gastrointestinal Disorders Market by Region
- 5.2.2 Global Metabolic Diseases Market by Region
- 5.2.3 Global Others Market by Region
- 5.3 Global Research Application Market by Region
- Chapter 6. Global Microbiome Diagnostics Market by Product
- 6.1 Global Reagents & Kits Market by Region
- 6.2 Global Instruments Market by Region
- Chapter 7. Global Microbiome Diagnostics Market by Sample
- 7.1 Global Fecal Market by Region
- 7.2 Global Saliva Market by Region
- 7.3 Global Skin Market by Region
- 7.4 Global Others Market by Region
- Chapter 8. Global Microbiome Diagnostics Market by Technology
- 8.1 Global 16S rRNA Sequencing Market by Region
- 8.2 Global Shot Gun Metagenomics Market by Region
- 8.3 Global Metatranscriptomics Market by Region
- 8.4 Global Others Market by Region
- Chapter 9. Global Microbiome Diagnostics Market by End User
- 9.1 Global Hospitals Market by Region
- 9.2 Global Academic & Research Institutes Market by Region
- 9.3 Global Biotechnology & Pharmaceutical Companies Market by Region
- Chapter 10. Global Microbiome Diagnostics Market by Region
- 10.1 North America Microbiome Diagnostics Market
- 10.1.1 North America Microbiome Diagnostics Market by Application
- 10.1.1.1 North America Disease Diagnostics Market by Region
- 10.1.1.2 North America Microbiome Diagnostics Market by Disease Diagnostics Type
- 10.1.1.2.1 North America Gastrointestinal Disorders Market by Country
- 10.1.1.2.2 North America Metabolic Diseases Market by Country
- 10.1.1.2.3 North America Others Market by Country
- 10.1.1.3 North America Research Application Market by Region
- 10.1.2 North America Microbiome Diagnostics Market by Product
- 10.1.2.1 North America Reagents & Kits Market by Country
- 10.1.2.2 North America Instruments Market by Country
- 10.1.3 North America Microbiome Diagnostics Market by Sample
- 10.1.3.1 North America Fecal Market by Country
- 10.1.3.2 North America Saliva Market by Country
- 10.1.3.3 North America Skin Market by Country
- 10.1.3.4 North America Others Market by Country
- 10.1.4 North America Microbiome Diagnostics Market by Technology
- 10.1.4.1 North America 16S rRNA Sequencing Market by Country
- 10.1.4.2 North America Shot Gun Metagenomics Market by Country
- 10.1.4.3 North America Metatranscriptomics Market by Country
- 10.1.4.4 North America Others Market by Country
- 10.1.5 North America Microbiome Diagnostics Market by End User
- 10.1.5.1 North America Hospitals Market by Country
- 10.1.5.2 North America Academic & Research Institutes Market by Country
- 10.1.5.3 North America Biotechnology & Pharmaceutical Companies Market by Country
- 10.1.6 North America Microbiome Diagnostics Market by Country
- 10.1.6.1 US Microbiome Diagnostics Market
- 10.1.6.1.1 US Microbiome Diagnostics Market by Application
- 10.1.6.1.2 US Microbiome Diagnostics Market by Product
- 10.1.6.1.3 US Microbiome Diagnostics Market by Sample
- 10.1.6.1.4 US Microbiome Diagnostics Market by Technology
- 10.1.6.1.5 US Microbiome Diagnostics Market by End User
- 10.1.6.2 Canada Microbiome Diagnostics Market
- 10.1.6.2.1 Canada Microbiome Diagnostics Market by Application
- 10.1.6.2.2 Canada Microbiome Diagnostics Market by Product
- 10.1.6.2.3 Canada Microbiome Diagnostics Market by Sample
- 10.1.6.2.4 Canada Microbiome Diagnostics Market by Technology
- 10.1.6.2.5 Canada Microbiome Diagnostics Market by End User
- 10.1.6.3 Mexico Microbiome Diagnostics Market
- 10.1.6.3.1 Mexico Microbiome Diagnostics Market by Application
- 10.1.6.3.2 Mexico Microbiome Diagnostics Market by Product
- 10.1.6.3.3 Mexico Microbiome Diagnostics Market by Sample
- 10.1.6.3.4 Mexico Microbiome Diagnostics Market by Technology
- 10.1.6.3.5 Mexico Microbiome Diagnostics Market by End User
- 10.1.6.4 Rest of North America Microbiome Diagnostics Market
- 10.1.6.4.1 Rest of North America Microbiome Diagnostics Market by Application
- 10.1.6.4.2 Rest of North America Microbiome Diagnostics Market by Product
- 10.1.6.4.3 Rest of North America Microbiome Diagnostics Market by Sample
- 10.1.6.4.4 Rest of North America Microbiome Diagnostics Market by Technology
- 10.1.6.4.5 Rest of North America Microbiome Diagnostics Market by End User
- 10.2 Europe Microbiome Diagnostics Market
- 10.2.1 Europe Microbiome Diagnostics Market by Application
- 10.2.1.1 Europe Disease Diagnostics Market by Country
- 10.2.1.2 Europe Microbiome Diagnostics Market by Disease Diagnostics Type
- 10.2.1.2.1 Europe Gastrointestinal Disorders Market by Country
- 10.2.1.2.2 Europe Metabolic Diseases Market by Country
- 10.2.1.2.3 Europe Others Market by Country
- 10.2.1.3 Europe Research Application Market by Country
- 10.2.2 Europe Microbiome Diagnostics Market by Product
- 10.2.2.1 Europe Reagents & Kits Market by Country
- 10.2.2.2 Europe Instruments Market by Country
- 10.2.3 Europe Microbiome Diagnostics Market by Sample
- 10.2.3.1 Europe Fecal Market by Country
- 10.2.3.2 Europe Saliva Market by Country
- 10.2.3.3 Europe Skin Market by Country
- 10.2.3.4 Europe Others Market by Country
- 10.2.4 Europe Microbiome Diagnostics Market by Technology
- 10.2.4.1 Europe 16S rRNA Sequencing Market by Country
- 10.2.4.2 Europe Shot Gun Metagenomics Market by Country
- 10.2.4.3 Europe Metatranscriptomics Market by Country
- 10.2.4.4 Europe Others Market by Country
- 10.2.5 Europe Microbiome Diagnostics Market by End User
- 10.2.5.1 Europe Hospitals Market by Country
- 10.2.5.2 Europe Academic & Research Institutes Market by Country
- 10.2.5.3 Europe Biotechnology & Pharmaceutical Companies Market by Country
- 10.2.6 Europe Microbiome Diagnostics Market by Country
- 10.2.6.1 Germany Microbiome Diagnostics Market
- 10.2.6.1.1 Germany Microbiome Diagnostics Market by Application
- 10.2.6.1.2 Germany Microbiome Diagnostics Market by Product
- 10.2.6.1.3 Germany Microbiome Diagnostics Market by Sample
- 10.2.6.1.4 Germany Microbiome Diagnostics Market by Technology
- 10.2.6.1.5 Germany Microbiome Diagnostics Market by End User
- 10.2.6.2 UK Microbiome Diagnostics Market
- 10.2.6.2.1 UK Microbiome Diagnostics Market by Application
- 10.2.6.2.2 UK Microbiome Diagnostics Market by Product
- 10.2.6.2.3 UK Microbiome Diagnostics Market by Sample
- 10.2.6.2.4 UK Microbiome Diagnostics Market by Technology
- 10.2.6.2.5 UK Microbiome Diagnostics Market by End User
- 10.2.6.3 France Microbiome Diagnostics Market
- 10.2.6.3.1 France Microbiome Diagnostics Market by Application
- 10.2.6.3.2 France Microbiome Diagnostics Market by Product
- 10.2.6.3.3 France Microbiome Diagnostics Market by Sample
- 10.2.6.3.4 France Microbiome Diagnostics Market by Technology
- 10.2.6.3.5 France Microbiome Diagnostics Market by End User
- 10.2.6.4 Russia Microbiome Diagnostics Market
- 10.2.6.4.1 Russia Microbiome Diagnostics Market by Application
- 10.2.6.4.2 Russia Microbiome Diagnostics Market by Product
- 10.2.6.4.3 Russia Microbiome Diagnostics Market by Sample
- 10.2.6.4.4 Russia Microbiome Diagnostics Market by Technology
- 10.2.6.4.5 Russia Microbiome Diagnostics Market by End User
- 10.2.6.5 Spain Microbiome Diagnostics Market
- 10.2.6.5.1 Spain Microbiome Diagnostics Market by Application
- 10.2.6.5.2 Spain Microbiome Diagnostics Market by Product
- 10.2.6.5.3 Spain Microbiome Diagnostics Market by Sample
- 10.2.6.5.4 Spain Microbiome Diagnostics Market by Technology
- 10.2.6.5.5 Spain Microbiome Diagnostics Market by End User
- 10.2.6.6 Italy Microbiome Diagnostics Market
- 10.2.6.6.1 Italy Microbiome Diagnostics Market by Application
- 10.2.6.6.2 Italy Microbiome Diagnostics Market by Product
- 10.2.6.6.3 Italy Microbiome Diagnostics Market by Sample
- 10.2.6.6.4 Italy Microbiome Diagnostics Market by Technology
- 10.2.6.6.5 Italy Microbiome Diagnostics Market by End User
- 10.2.6.7 Rest of Europe Microbiome Diagnostics Market
- 10.2.6.7.1 Rest of Europe Microbiome Diagnostics Market by Application
- 10.2.6.7.2 Rest of Europe Microbiome Diagnostics Market by Product
- 10.2.6.7.3 Rest of Europe Microbiome Diagnostics Market by Sample
- 10.2.6.7.4 Rest of Europe Microbiome Diagnostics Market by Technology
- 10.2.6.7.5 Rest of Europe Microbiome Diagnostics Market by End User
- 10.3 Asia Pacific Microbiome Diagnostics Market
- 10.3.1 Asia Pacific Microbiome Diagnostics Market by Application
- 10.3.1.1 Asia Pacific Disease Diagnostics Market by Country
- 10.3.1.2 Asia Pacific Microbiome Diagnostics Market by Disease Diagnostics Type
- 10.3.1.2.1 Asia Pacific Gastrointestinal Disorders Market by Country
- 10.3.1.2.2 Asia Pacific Metabolic Diseases Market by Country
- 10.3.1.2.3 Asia Pacific Others Market by Country
- 10.3.1.3 Asia Pacific Research Application Market by Country
- 10.3.2 Asia Pacific Microbiome Diagnostics Market by Product
- 10.3.2.1 Asia Pacific Reagents & Kits Market by Country
- 10.3.2.2 Asia Pacific Instruments Market by Country
- 10.3.3 Asia Pacific Microbiome Diagnostics Market by Sample
- 10.3.3.1 Asia Pacific Fecal Market by Country
- 10.3.3.2 Asia Pacific Saliva Market by Country
- 10.3.3.3 Asia Pacific Skin Market by Country
- 10.3.3.4 Asia Pacific Others Market by Country
- 10.3.4 Asia Pacific Microbiome Diagnostics Market by Technology
- 10.3.4.1 Asia Pacific 16S rRNA Sequencing Market by Country
- 10.3.4.2 Asia Pacific Shot Gun Metagenomics Market by Country
- 10.3.4.3 Asia Pacific Metatranscriptomics Market by Country
- 10.3.4.4 Asia Pacific Others Market by Country
- 10.3.5 Asia Pacific Microbiome Diagnostics Market by End User
- 10.3.5.1 Asia Pacific Hospitals Market by Country
- 10.3.5.2 Asia Pacific Academic & Research Institutes Market by Country
- 10.3.5.3 Asia Pacific Biotechnology & Pharmaceutical Companies Market by Country
- 10.3.6 Asia Pacific Microbiome Diagnostics Market by Country
- 10.3.6.1 China Microbiome Diagnostics Market
- 10.3.6.1.1 China Microbiome Diagnostics Market by Application
- 10.3.6.1.2 China Microbiome Diagnostics Market by Product
- 10.3.6.1.3 China Microbiome Diagnostics Market by Sample
- 10.3.6.1.4 China Microbiome Diagnostics Market by Technology
- 10.3.6.1.5 China Microbiome Diagnostics Market by End User
- 10.3.6.2 Japan Microbiome Diagnostics Market
- 10.3.6.2.1 Japan Microbiome Diagnostics Market by Application
- 10.3.6.2.2 Japan Microbiome Diagnostics Market by Product
- 10.3.6.2.3 Japan Microbiome Diagnostics Market by Sample
- 10.3.6.2.4 Japan Microbiome Diagnostics Market by Technology
- 10.3.6.2.5 Japan Microbiome Diagnostics Market by End User
- 10.3.6.3 India Microbiome Diagnostics Market
- 10.3.6.3.1 India Microbiome Diagnostics Market by Application
- 10.3.6.3.2 India Microbiome Diagnostics Market by Product
- 10.3.6.3.3 India Microbiome Diagnostics Market by Sample
- 10.3.6.3.4 India Microbiome Diagnostics Market by Technology
- 10.3.6.3.5 India Microbiome Diagnostics Market by End User
- 10.3.6.4 South Korea Microbiome Diagnostics Market
- 10.3.6.4.1 South Korea Microbiome Diagnostics Market by Application
- 10.3.6.4.2 South Korea Microbiome Diagnostics Market by Product
- 10.3.6.4.3 South Korea Microbiome Diagnostics Market by Sample
- 10.3.6.4.4 South Korea Microbiome Diagnostics Market by Technology
- 10.3.6.4.5 South Korea Microbiome Diagnostics Market by End User
- 10.3.6.5 Australia Microbiome Diagnostics Market
- 10.3.6.5.1 Australia Microbiome Diagnostics Market by Application
- 10.3.6.5.2 Australia Microbiome Diagnostics Market by Product
- 10.3.6.5.3 Australia Microbiome Diagnostics Market by Sample
- 10.3.6.5.4 Australia Microbiome Diagnostics Market by Technology
- 10.3.6.5.5 Australia Microbiome Diagnostics Market by End User
- 10.3.6.6 Malaysia Microbiome Diagnostics Market
- 10.3.6.6.1 Malaysia Microbiome Diagnostics Market by Application
- 10.3.6.6.2 Malaysia Microbiome Diagnostics Market by Product
- 10.3.6.6.3 Malaysia Microbiome Diagnostics Market by Sample
- 10.3.6.6.4 Malaysia Microbiome Diagnostics Market by Technology
- 10.3.6.6.5 Malaysia Microbiome Diagnostics Market by End User
- 10.3.6.7 Rest of Asia Pacific Microbiome Diagnostics Market
- 10.3.6.7.1 Rest of Asia Pacific Microbiome Diagnostics Market by Application
- 10.3.6.7.2 Rest of Asia Pacific Microbiome Diagnostics Market by Product
- 10.3.6.7.3 Rest of Asia Pacific Microbiome Diagnostics Market by Sample
- 10.3.6.7.4 Rest of Asia Pacific Microbiome Diagnostics Market by Technology
- 10.3.6.7.5 Rest of Asia Pacific Microbiome Diagnostics Market by End User
- 10.4 LAMEA Microbiome Diagnostics Market
- 10.4.1 LAMEA Microbiome Diagnostics Market by Application
- 10.4.1.1 LAMEA Disease Diagnostics Market by Country
- 10.4.1.2 LAMEA Microbiome Diagnostics Market by Disease Diagnostics Type
- 10.4.1.2.1 LAMEA Gastrointestinal Disorders Market by Country
- 10.4.1.2.2 LAMEA Metabolic Diseases Market by Country
- 10.4.1.2.3 LAMEA Others Market by Country
- 10.4.1.3 LAMEA Research Application Market by Country
- 10.4.2 LAMEA Microbiome Diagnostics Market by Product
- 10.4.2.1 LAMEA Reagents & Kits Market by Country
- 10.4.2.2 LAMEA Instruments Market by Country
- 10.4.3 LAMEA Microbiome Diagnostics Market by Sample
- 10.4.3.1 LAMEA Fecal Market by Country
- 10.4.3.2 LAMEA Saliva Market by Country
- 10.4.3.3 LAMEA Skin Market by Country
- 10.4.3.4 LAMEA Others Market by Country
- 10.4.4 LAMEA Microbiome Diagnostics Market by Technology
- 10.4.4.1 LAMEA 16S rRNA Sequencing Market by Country
- 10.4.4.2 LAMEA Shot Gun Metagenomics Market by Country
- 10.4.4.3 LAMEA Metatranscriptomics Market by Country
- 10.4.4.4 LAMEA Others Market by Country
- 10.4.5 LAMEA Microbiome Diagnostics Market by End User
- 10.4.5.1 LAMEA Hospitals Market by Country
- 10.4.5.2 LAMEA Academic & Research Institutes Market by Country
- 10.4.5.3 LAMEA Biotechnology & Pharmaceutical Companies Market by Country
- 10.4.6 LAMEA Microbiome Diagnostics Market by Country
- 10.4.6.1 Brazil Microbiome Diagnostics Market
- 10.4.6.1.1 Brazil Microbiome Diagnostics Market by Application
- 10.4.6.1.2 Brazil Microbiome Diagnostics Market by Product
- 10.4.6.1.3 Brazil Microbiome Diagnostics Market by Sample
- 10.4.6.1.4 Brazil Microbiome Diagnostics Market by Technology
- 10.4.6.1.5 Brazil Microbiome Diagnostics Market by End User
- 10.4.6.2 Argentina Microbiome Diagnostics Market
- 10.4.6.2.1 Argentina Microbiome Diagnostics Market by Application
- 10.4.6.2.2 Argentina Microbiome Diagnostics Market by Product
- 10.4.6.2.3 Argentina Microbiome Diagnostics Market by Sample
- 10.4.6.2.4 Argentina Microbiome Diagnostics Market by Technology
- 10.4.6.2.5 Argentina Microbiome Diagnostics Market by End User
- 10.4.6.3 UAE Microbiome Diagnostics Market
- 10.4.6.3.1 UAE Microbiome Diagnostics Market by Application
- 10.4.6.3.2 UAE Microbiome Diagnostics Market by Product
- 10.4.6.3.3 UAE Microbiome Diagnostics Market by Sample
- 10.4.6.3.4 UAE Microbiome Diagnostics Market by Technology
- 10.4.6.3.5 UAE Microbiome Diagnostics Market by End User
- 10.4.6.4 Saudi Arabia Microbiome Diagnostics Market
- 10.4.6.4.1 Saudi Arabia Microbiome Diagnostics Market by Application
- 10.4.6.4.2 Saudi Arabia Microbiome Diagnostics Market by Product
- 10.4.6.4.3 Saudi Arabia Microbiome Diagnostics Market by Sample
- 10.4.6.4.4 Saudi Arabia Microbiome Diagnostics Market by Technology
- 10.4.6.4.5 Saudi Arabia Microbiome Diagnostics Market by End User
- 10.4.6.5 South Africa Microbiome Diagnostics Market
- 10.4.6.5.1 South Africa Microbiome Diagnostics Market by Application
- 10.4.6.5.2 South Africa Microbiome Diagnostics Market by Product
- 10.4.6.5.3 South Africa Microbiome Diagnostics Market by Sample
- 10.4.6.5.4 South Africa Microbiome Diagnostics Market by Technology
- 10.4.6.5.5 South Africa Microbiome Diagnostics Market by End User
- 10.4.6.6 Nigeria Microbiome Diagnostics Market
- 10.4.6.6.1 Nigeria Microbiome Diagnostics Market by Application
- 10.4.6.6.2 Nigeria Microbiome Diagnostics Market by Product
- 10.4.6.6.3 Nigeria Microbiome Diagnostics Market by Sample
- 10.4.6.6.4 Nigeria Microbiome Diagnostics Market by Technology
- 10.4.6.6.5 Nigeria Microbiome Diagnostics Market by End User
- 10.4.6.7 Rest of LAMEA Microbiome Diagnostics Market
- 10.4.6.7.1 Rest of LAMEA Microbiome Diagnostics Market by Application
- 10.4.6.7.2 Rest of LAMEA Microbiome Diagnostics Market by Product
- 10.4.6.7.3 Rest of LAMEA Microbiome Diagnostics Market by Sample
- 10.4.6.7.4 Rest of LAMEA Microbiome Diagnostics Market by Technology
- 10.4.6.7.5 Rest of LAMEA Microbiome Diagnostics Market by End User
- Chapter 11. Company Profiles
- 11.1 Illumina, Inc.
- 11.1.1 Company Overview
- 11.1.2 Financial Analysis
- 11.1.3 Regional Analysis
- 11.1.4 Research & Development Expense
- 11.1.5 Recent strategies and developments:
- 11.1.5.1 Partnerships, Collaborations, and Agreements:
- 11.1.6 SWOT Analysis
- 11.2 Becton, Dickinson, and Company
- 11.2.1 Company Overview
- 11.2.2 Financial Analysis
- 11.2.3 Segmental and Regional Analysis
- 11.2.4 Research & Development Expense
- 11.2.5 Recent strategies and developments:
- 11.2.5.1 Product Launches and Product Expansions:
- 11.2.5.2 Trails and Approvals:
- 11.2.6 SWOT Analysis
- 11.3 Genetic Analysis AS
- 11.3.1 Company Overview
- 11.3.2 Financial Analysis
- 11.3.3 Regional Analysis
- 11.3.4 Recent strategies and developments:
- 11.3.4.1 Partnerships, Collaborations, and Agreements:
- 11.4 Microba Life Sciences Limited
- 11.4.1 Company Overview
- 11.4.2 Financial Analysis
- 11.4.3 Regional Analysis
- 11.4.4 Research & Development Expenses
- 11.4.5 Recent strategies and developments:
- 11.4.5.1 Partnerships, Collaborations, and Agreements:
- 11.4.5.2 Product Launches and Product Expansions:
- 11.5 BioMe Oxford Ltd
- 11.5.1 Company Overview
- 11.5.2 Recent strategies and developments:
- 11.5.2.1 Partnerships, Collaborations, and Agreements:
- 11.6 Viome Life Sciences, Inc.
- 11.6.1 Company Overview
- 11.6.2 Recent strategies and developments:
- 11.6.2.1 Product Launches and Product Expansions:
- 11.6.2.2 Acquisition and Mergers:
- 11.7 GoodGut S.L.U. (HIPRA, S.A.)
- 11.7.1 Company Overview
- 11.8 Sun Genomics
- 11.8.1 Company Overview
- 11.9 Origin Sciences Limited
- 11.9.1 Company Overview
- 11.10. Decode Age
- 11.10.1 Company Overview
- Chapter 12. Winning imperatives of Microbiome Diagnostics Market
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.